15.02.2025
В. И. Вечорко; Д. А. Сычёв; И. С. Кицул; Т. А. Чеботарёва
and surgeries, and condition of patients. The most expensive is the management of patients with COVID-19
13.02.2025
Д. Ф. Нурхаметова; Е. В. Юдина; Л. Е. Зиганшина; Д. А. Сычёв
by healthcare systems during the COVID-19 pandemic, the Global Commission on Evidence was established. Its work
07.01.2022
И. И. Темирбулатов; А. В. Крюков; Д. А. Сычёв
and safety of COVID-19 therapy. Clinical studies of remdesivir and favipiravir are reviewed. Potential
28.10.2020
В. А. Отделенов; К. Б. Мирзаев; Д. А. Сычёв
Use of canakinumab in patients with COVID-19 is currently lacking proper evidence base, and should
28.10.2020
В. А. Отделенов; Ю. Ю. Киселёв; К. Б. Мирзаев; А. В. Матвеев; Д. А. Сычёв
of hydroxychloroquine, especially if combined with azithromycin, for COVID-19. Such treatment may be associated
28.10.2020
В. А. Отделенов; А. В. Матвеев; Д. А. Сычёв
treatment of “cytokine storm” in severe COVID-19.
28.10.2020
А. В. Крюков; В. А. Отделенов; Д. А. Сычёв
We present anticoagulant outpatient deprescribing algorithm in patients with COVID-19 discharged
28.10.2020
В. М. Цветов; А. В. Матвеев; Д. А. Сычёв
Routine clinical use of olokizumab in COVID-19 is not recommended. The use of olokizumab
28.10.2020
Ю. Ю. Киселёв; А. В. Матвеев; Д. А. Сычёв
There exist some theoretical premises for the use of colchicine in patients with COVID-19
28.10.2020
Ю. Ю. Киселёв; К. А. Загородникова; Д. В. Иващенко; А. В. Крюков; И. Н. Сычёв; А. С. Матвеев; К. Б. Мирзаев; В. А. Отделенов; В. М. Цветов; А. В. Дмитриев; В. В. Поройков; Д. А. Сычёв
At the time of print, the evidence for using umifenovir in COVID-19 is mainly theoretical
